GILD

GILEAD SCIENCES, INC.

GILEAD SCIENCES, INC. (GILD) has 9 SEC Form 4 filings (29 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 16, 2026.

The most active filer is Chief Financial Officer Dickinson Andrew D with 3 filings. Insiders have net sold $8.4M over the trailing 6 months.

  • Industry:Drug Manufacturers - General
  • CEO:Daniel O'Day
  • Employees:17,600
  • HQ:Foster City, CA, US
  • IPO:1992-01-22

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$18.2M

reported sales (SEC code S)

Unique Insiders

4

in the rolling window

Market Cap

$169.2B

latest known value

Source
Sale$390KJul 16SEC ↗
Sale$390KJul 16SEC ↗
Sale$1.9MJul 2SEC ↗
Sale$376KJun 16SEC ↗
Dickinson Andrew DFirst filing
Sale$397KMay 18SEC ↗
Mercier JohannaFirst in 9 months
Sale$3.7MMay 18SEC ↗
Sale$1.3MApr 29SEC ↗
Telman Deborah HFirst filing
Sale$6.6MNov 13SEC ↗
Mercier JohannaFirst filing
Sale$3.2MAug 18SEC ↗

Congress trading GILD

See timeline →
  • DRep. Jared MoskowitzPurchase$1,001 - $15,0002026-05-06

STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.

Related companies

GILEAD SCIENCES, INC. is in the Healthcare sector.